

Daniel Souery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8825076/publications.pdf>

Version: 2024-02-01

166
papers

7,401
citations

57758

44
h-index

64796

79
g-index

188
all docs

188
docs citations

188
times ranked

7396
citing authors

#	ARTICLE	IF	CITATIONS
1	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. <i>American Journal of Psychiatry</i> , 2013, 170, 1249-1262.	7.2	579
2	Clinical Factors Associated With Treatment Resistance in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1062-1070.	2.2	407
3	An Inflammatory Biomarker as a Differential Predictor of Outcome of Depression Treatment With Escitalopram and Nortriptyline. <i>American Journal of Psychiatry</i> , 2014, 171, 1278-1286.	7.2	336
4	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. <i>American Journal of Psychiatry</i> , 2010, 167, 555-564.	7.2	314
5	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. <i>American Journal of Psychiatry</i> , 2013, 170, 207-217.	7.2	216
6	Adverse reactions to antidepressants. <i>British Journal of Psychiatry</i> , 2009, 195, 202-210.	2.8	205
7	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 344-350.	4.1	202
8	Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. <i>International Clinical Psychopharmacology</i> , 2006, 21, 227-231.	1.7	199
9	Genetic predictors of response to antidepressants in the GENDEP project. <i>Pharmacogenomics Journal</i> , 2009, 9, 225-233.	2.0	188
10	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. <i>British Journal of Psychiatry</i> , 2009, 194, 252-259.	2.8	170
11	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. <i>Journal of Psychiatric Research</i> , 2016, 78, 94-102.	3.1	149
12	Moderation of antidepressant response by the serotonin transporter gene. <i>British Journal of Psychiatry</i> , 2009, 195, 30-38.	2.8	143
13	European Group for the Study of Resistant Depression (GSRD) – Where have we gone so far: Review of clinical and genetic findings. <i>European Neuropsychopharmacology</i> , 2012, 22, 453-468.	0.7	111
14	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001326.	8.4	110
15	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. <i>Journal of Affective Disorders</i> , 2011, 132, 112-120.	4.1	93
16	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	4.5	92
17	Body weight as a predictor of antidepressant efficacy in the GENDEP project. <i>Journal of Affective Disorders</i> , 2009, 118, 147-154.	4.1	89
18	Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 427-448.	2.6	89

#	ARTICLE	IF	CITATIONS
19	Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 512-516.	1.4	83
20	Treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 6, 16-22.	2.2	83
21	Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. <i>Journal of Psychopharmacology</i> , 2012, 26, 603-617.	4.0	81
22	Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. <i>European Journal of Human Genetics</i> , 2004, 12, 377-382.	2.8	78
23	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 441-453.	0.7	77
24	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017, 91, 1-13.	3.1	77
25	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	2.2	76
26	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. <i>Journal of Psychopharmacology</i> , 2014, 28, 133-141.	4.0	75
27	Linkage analysis of families with bipolar illness and chromosome 18 markers. <i>Biological Psychiatry</i> , 1996, 39, 679-688.	1.3	73
28	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016, 189, 224-232.	4.1	73
29	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 215-222.	2.2	73
30	Pharmacogenetics of antidepressant response: A polygenic approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 128-134.	4.8	71
31	Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. <i>International Clinical Psychopharmacology</i> , 2009, 24, 250-256.	1.7	69
32	Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes. , 1996, 67, 551-555.		67
33	Brain-derived neurotrophic factor gene polymorphisms. <i>International Clinical Psychopharmacology</i> , 2011, 26, 1-10.	1.7	67
34	Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study. <i>Biological Psychiatry</i> , 2001, 49, 405-409.	1.3	66
35	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. <i>European Neuropsychopharmacology</i> , 2018, 28, 945-954.	0.7	64
36	Non-replication of the brain-derived neurotrophic factor (BDNF) association in bipolar affective disorder: A Belgian patient-control study. <i>American Journal of Medical Genetics Part A</i> , 2004, 129B, 34-35.	2.4	62

#	ARTICLE	IF	CITATIONS
37	Current issues in bipolar disorder: A critical review. <i>European Neuropsychopharmacology</i> , 2007, 17, 687-695.	0.7	56
38	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 539-549.	2.1	54
39	Expanded trinucleotide CAG repeats in families with bipolar affective disorder. <i>Biological Psychiatry</i> , 1997, 42, 1115-1122.	1.3	53
40	The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case-control association study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 218-227.	1.7	51
41	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. <i>Scientific Reports</i> , 2018, 8, 5530.	3.3	51
42	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European multicenter association study of affective disorders. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 177-185.	2.4	50
43	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016, 26, 1960-1971.	0.7	50
44	Social adjustment and self-esteem in remitted patients with unipolar and bipolar affective disorder: A case-control study. <i>Comprehensive Psychiatry</i> , 1999, 40, 24-30.	3.1	49
45	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018, 28, 752-760.	0.7	47
46	A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression. <i>Journal of Affective Disorders</i> , 2011, 128, 56-63.	4.1	45
47	No association between bipolar affective disorder and a serotonin receptor (5-HT2A) polymorphism. <i>Psychiatry Research</i> , 1997, 70, 65-69.	3.3	44
48	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	2.8	44
49	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014, 14, 463-472.	2.0	41
50	Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 364-375.	2.6	40
51	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. , 2000, 96, 136-140.		38
52	The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder – A European Multicenter Study. <i>European Neuropsychopharmacology</i> , 2012, 22, 259-266.	0.7	38
53	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 271-278.	4.8	38
54	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015, 184, 51-59.	4.1	38

#	ARTICLE	IF	CITATIONS
55	Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-15.	2.6	38
56	5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2010, 25, 228-231.	1.7	37
57	Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 401-412.	4.5	37
58	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110170.	4.8	36
59	Depression across mood disorders: review and analysis in a clinical sample. <i>Comprehensive Psychiatry</i> , 2012, 53, 24-38.	3.1	34
60	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015, 15, 538-548.	2.0	34
61	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	4.8	33
62	COMT and age at onset in mood disorders: A replication and extension study. <i>Neuroscience Letters</i> , 2011, 498, 218-221.	2.1	32
63	Clinical and genetic factors associated with suicide in mood disorder patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 181-193.	3.2	32
64	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018, 227, 777-786.	4.1	32
65	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 93-104.	2.1	32
66	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109835.	4.8	32
67	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the <i>5-HTTLPR</i>. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 528-538.	2.6	31
68	Exploring the role of drug-metabolising enzymes in antidepressant side effects. <i>Psychopharmacology</i> , 2015, 232, 2609-2617.	3.1	31
69	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	4.8	31
70	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	2.2	31
71	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016, 204, 54-58.	4.1	30
72	Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features. <i>Journal of Affective Disorders</i> , 2011, 135, 241-250.	4.1	29

#	ARTICLE	IF	CITATIONS
73	Molecular genetics in the analysis of suicide. <i>Annals of Medicine</i> , 2003, 35, 191-196.	3.8	28
74	Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder. <i>European Neuropsychopharmacology</i> , 2013, 23, 895-901.	0.7	28
75	Psychotic Features in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	28
76	Molecular Interpretation of Expanded RED Products in Bipolar Disorder by CAG/CTG Repeats Located at Chromosomes 17q and 18q. <i>Neurobiology of Disease</i> , 1999, 6, 424-432.	4.4	27
77	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019, 252, 464-474.	4.1	27
78	Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 93-103.	3.2	24
79	Dissociation in Major Depressive Disorder: A Pilot Study. <i>Journal of Trauma and Dissociation</i> , 2008, 9, 411-421.	1.9	22
80	Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression. <i>Neuropsychobiology</i> , 2012, 65, 70-75.	1.9	22
81	Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression. <i>Neuroscience Letters</i> , 2012, 516, 85-88.	2.1	21
82	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 723-735.	3.2	21
83	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110050.	4.8	21
84	Lack of association between the 5HT2A receptor polymorphism (T102C) and unipolar affective disorder in a multicentric European study. <i>European Neuropsychopharmacology</i> , 2003, 13, 365-368.	0.7	20
85	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 94, 109638.	4.8	20
86	Genetic refinement and physical mapping of a chromosome 18q candidate region for bipolar disorder. <i>European Journal of Human Genetics</i> , 1999, 7, 427-434.	2.8	19
87	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. <i>Journal of Psychopharmacology</i> , 2013, 27, 616-628.	4.0	19
88	The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study. <i>International Clinical Psychopharmacology</i> , 2016, 31, 1-7.	1.7	19
89	Transcriptomics and the mechanisms of antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2016, 26, 105-112.	0.7	19
90	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017, 27, 625-632.	0.7	19

#	ARTICLE	IF	CITATIONS
91	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). <i>Translational Psychiatry</i> , 2018, 8, 150.	4.8	19
92	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.7	19
93	Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 297-301.	1.7	18
94	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. <i>Journal of Psychopharmacology</i> , 2014, 28, 142-150.	4.0	18
95	Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019, 29, 777-785.	0.7	18
96	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	4.1	18
97	Short-term and long-term treatment for bipolar patients: beyond the guidelines. <i>Journal of Affective Disorders</i> , 1999, 55, 79-85.	4.1	17
98	Predominant polarity in bipolar disorder patients: The COPE bipolar sample. <i>Journal of Affective Disorders</i> , 2019, 250, 43-50.	4.1	17
99	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	4.8	17
100	The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk – a European multicentre study on treatment-resistant major depressive disorder. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 385-391.	3.2	16
101	Compliance and therapeutic issues in resistant depression. <i>International Clinical Psychopharmacology</i> , 1998, 13, S13-S18.	1.7	15
102	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 472-482.	2.6	15
103	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018, 28, 1305-1313.	0.7	15
104	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 48-52.	2.0	15
105	Methodology for clinical genotyping of CYP2D6 and CYP2C19. <i>Translational Psychiatry</i> , 2021, 11, 596.	4.8	15
106	Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. <i>Journal of Affective Disorders</i> , 2013, 150, 649-652.	4.1	14
107	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. <i>Journal of Neural Transmission</i> , 2015, 122, 43-58.	2.8	14
108	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.7	14

#	ARTICLE	IF	CITATIONS
109	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	3.1	14
110	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	3.2	14
111	The characterization and definition of treatment-resistant mood disorders. , 2001, , 3-29.		13
112	The Multiple Facets of Treatment-Resistant Depression. <i>CNS Spectrums</i> , 2004, 9, 803-807.	1.2	10
113	No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression. <i>Psychiatry Research</i> , 2011, 188, 166-169.	3.3	10
114	The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients. <i>Psychopathology</i> , 2013, 46, 384-389.	1.5	10
115	The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 782-787.	2.1	10
116	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. <i>British Journal of Psychiatry</i> , 2019, 215, 494-501.	2.8	10
117	Fluvoxamine-induced hyperglycaemia in a diabetic patient with comorbid depression. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 85-87.	2.1	9
118	Molecular genetics of affective disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 865-877.	4.8	9
119	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	2.1	9
120	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. <i>International Clinical Psychopharmacology</i> , 2022, 37, 38-45.	1.7	9
121	No evidence for the involvement of CAG/CTG repeats from within 18q21.33â€“q23 in bipolar disorder. <i>European Journal of Human Genetics</i> , 2000, 8, 385-388.	2.8	8
122	Family history of major depression and residual symptoms in responder and non-responder depressed patients. <i>Comprehensive Psychiatry</i> , 2014, 55, 51-55.	3.1	8
123	High occupational level is associated with poor response to treatment of depression. <i>European Neuropsychopharmacology</i> , 2016, 26, 1320-1326.	0.7	8
124	Opinion paper: poor response to treatment of depression in people in high occupational levels. <i>Psychological Medicine</i> , 2019, 49, 49-54.	4.5	8
125	Polygenic risk scores for neuropsychiatric, inflammatory, and cardioâ€“metabolic traits highlight possible genetic overlap with suicide attempt and treatmentâ€“emergent suicidal ideation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 74-85.	1.7	8
126	Molecular genetics of affective disorders. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 155-169.	2.1	7

#	ARTICLE	IF	CITATIONS
127	Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression. <i>International Journal of Neuroscience</i> , 2015, 125, 336-343.	1.6	7
128	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	1.5	7
129	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	7
130	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021, 279, 722-729.	4.1	7
131	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018, 227, 254-259.	4.1	6
132	A New Characterization of Mental Health Disorders Using Digital Behavioral Data: Evidence from Major Depressive Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 3109.	2.4	6
133	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	2.1	5
134	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. <i>European Neuropsychopharmacology</i> , 2022, 56, 100-111.	0.7	5
135	Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 97-106.	0.6	5
136	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	4.1	4
137	Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. <i>Annals of Clinical Psychiatry</i> , 2014, 26, 243-53.	0.6	4
138	High occupational level is associated with poor response to the treatment of depression: A replication study. <i>European Neuropsychopharmacology</i> , 2019, 29, 349-355.	0.7	3
139	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	4.1	3
140	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	4.8	3
141	Introduction to the Special Section New advances in the understanding and treatment of bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 123-125.	2.1	2
142	Social adjustment among treatment responder patients with mood disorders. <i>Journal of Affective Disorders</i> , 2013, 150, 961-966.	4.1	2
143	Possible Modulatory Role of ARC Gene Variants in Mood Disorders. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 46-52.	2.0	2
144	A European multicenter association study of HTR2A receptor polymorphism in bipolar affective disorder. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 136-140.	2.4	2

#	ARTICLE	IF	CITATIONS
145	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	2.1	2
146	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. <i>Journal of Affective Disorders</i> , 2022, 312, 225-234.	4.1	2
147	Molecular genetics of affective disorders. <i>Current Opinion in Psychiatry</i> , 2003, 16, S63-S70.	6.3	1
148	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	2.4	1
149	Definition criteria for treatment resistant depression. <i>European Psychiatry</i> , 1998, 13, 206S-206S.	0.2	0
150	Treatment-Resistant Mood Disorders: From Diagnosis to Treatment. , 2005, , 373-401.		0
151	Role of risperidone in the treatment of bipolar disorder. <i>Future Neurology</i> , 2006, 1, 535-543.	0.5	0
152	Pharmacogenetics of bipolar disorders. , 2006, , 75-100.		0
153	FC04-06 - Candidate gene association study of suicidality in treatment resistant MDD. <i>European Psychiatry</i> , 2011, 26, 1833-1833.	0.2	0
154	Clinical and healthcare burden in patients with bipolar disorder. <i>International Clinical Psychopharmacology</i> , 2011, 26, e44.	1.7	0
155	Bipolar disorder therapy in daily clinical practice. <i>International Clinical Psychopharmacology</i> , 2011, 26, e44-e45.	1.7	0
156	Prescribing patterns of psychiatric drugs in major depressive disorder—Findings from a large European multicenter, cross-sectional study. <i>European Psychiatry</i> , 2017, 41, S367-S367.	0.2	0
157	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S1166-S1167.	0.7	0
158	F93. CYP2D6 Revisited in GENDEP, a Multicenter Clinical Trial of Nortriptyline and Escitalopram. <i>Biological Psychiatry</i> , 2019, 85, S248-S249.	1.3	0
159	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S934-S935.	0.7	0
160	M74 HIGHER POLYGENIC RISK SCORES FOR SCHIZOPHRENIA MAY BE SUGGESTIVE OF NON-RESPONSE TO DRUGS FOR DEPRESSION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER. <i>European Neuropsychopharmacology</i> , 2019, 29, S206-S207.	0.7	0
161	Attrition in treatment-resistant depression. <i>International Clinical Psychopharmacology</i> , 2019, 34, 161-169.	1.7	0
162	P.179 Polygenic risk scores for multiple psychiatric, inflammatory and cardio-metabolic traits highlight possible genetic overlap with suicide attempt. <i>European Neuropsychopharmacology</i> , 2020, 40, S105-S106.	0.7	0

#	ARTICLE	IF	CITATIONS
163	CYP2D6 Revisited in GENDEP: Inter-Platform Concordance. <i>Biological Psychiatry</i> , 2020, 87, S148.	1.3	0
164	Interactions des gènes et de l'environnement dans les troubles du comportement. <i>Cahiers De Psychologie Clinique</i> , 2001, n° 16, 25-32.	0.1	0
165	Genetic aetiology of mood disorders. , 2012, , 650-658.		0
166	Pharmacogenetics of Bipolar Disorder. , 0, , 75-100.		0